Global Neglected Tropical Disease Treatment Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Disease;

Dengue, Rabies, Trachoma, Buruli ulcer, Yaws, Leprosy, Chagas disease, Human African trypanosomiasis (sleeping sickness), Leishmaniases, Soil-transmitted helminthiases, and Others.

By Product Type;

Drugs and Vaccines.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn742115966 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Neglected Tropical Disease Treatment Market (USD Million), 2021 - 2031

In the year 2024, the Global Neglected Tropical Disease Treatment Market was valued at USD 2,240.76 million. The size of this market is expected to increase to USD 3,195.25 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 5.2%.

The Global Neglected Tropical Disease (NTD) Treatment Market represents a critical frontier in global healthcare, addressing a group of debilitating diseases that primarily affect populations in low-resource settings. Neglected tropical diseases encompass a diverse range of infectious illnesses such as Dengue, Rabies, Chagas disease, Leishmaniases, and others, often neglected due to their prevalence in impoverished regions and limited financial incentives for research and development. Despite their neglect, these diseases impose a significant burden on public health, leading to long-term disability, mortality, and economic hardships in affected communities. The Global NTD Treatment Market endeavors to combat these diseases through innovative treatments, preventive measures, and collaborative initiatives aimed at improving healthcare access and outcomes for vulnerable populations worldwide.

The Global Neglected Tropical Disease Treatment Market is characterized by a multifaceted approach that encompasses pharmaceutical interventions, vaccine development, vector control strategies, and public health initiatives. Pharmaceutical companies, research institutions, non-governmental organizations (NGOs), and governmental agencies collaborate to develop and deliver effective treatments, diagnostics, and preventive measures for neglected tropical diseases. This collaborative effort extends beyond traditional healthcare models, involving cross-sector partnerships, advocacy campaigns, and global health initiatives that prioritize equity, inclusivity, and sustainability in addressing NTDs.

Despite significant progress in NTD treatment and control efforts, challenges persist, including funding gaps, limited healthcare infrastructure, regulatory complexities, and disease endemicity. The Global Neglected Tropical Disease Treatment Market aims to overcome these challenges through innovative financing mechanisms, capacity-building initiatives, technology-driven solutions, and policy reforms that promote research, access to affordable treatments, and community-centered healthcare approaches. As the global healthcare community continues to prioritize neglected tropical diseases as a public health priority, the Global NTD Treatment Market plays a vital role in advancing health equity, reducing disease burden, and achieving sustainable development goals for the most vulnerable populations worldwide.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Disease
    2. Market Snapshot, By Product Type
    3. Market Snapshot, By Region
  4. Global Neglected Tropical Disease Treatment Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Government Initiatives
        2. Increased Funding
        3. Technological Advancements
        4. Awareness Campaigns
        5. Collaborative Partnerships
      2. Restraints
        1. Limited Access
        2. Healthcare Infrastructure
        3. Regulatory Challenges
        4. Funding Gaps
        5. Treatment Complexity
      3. Opportunities
        1. Novel Therapies
        2. Public-Private Partnerships
        3. Telemedicine Solutions
        4. Community Engagement
        5. Research Advancements
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Neglected Tropical Disease Treatment Market, By Disease, 2021 - 2031 (USD Million)
      1. Dengue
      2. Rabies
      3. Trachoma
      4. Buruli ulcer
      5. Yaws
      6. Leprosy
      7. Chagas disease
      8. Human African trypanosomiasis (sleeping sickness)
      9. Leishmaniases
      10. Soil-transmitted helminthiases
      11. Others.
    2. Global Neglected Tropical Disease Treatment Market, By Product Type, 2021 - 2031 (USD Million)
      1. Drugs
      2. Vaccines.
    3. Global Neglected Tropical Disease Treatment Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. GlaxoSmithKline plc
      2. Novartis AG
      3. Merck & Co., Inc.
      4. Bayer AG
      5. Pfizer Inc.
      6. Sanofi SA
      7. Johnson & Johnson
      8. AbbVie Inc.
      9. Gilead Sciences, Inc.
      10. Takeda Pharmaceutical Company Limited
  7. Analyst Views
  8. Future Outlook of the Market